Global Information
회사소개 | 문의

세계의 혈액 스크리닝 시장 예측(-2021년) : 기술별(핵산증폭(rPCR), ELISA(CLIA, 형광측정), 신속검사, NGS, 웨스턴블로팅), 제품별(설비, 시약 및 키트, 소프트웨어), 최종사용자별(혈액은행, 병원)

Blood Screening Market by Technology (Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecasts to 2021

리서치사 MarketsandMarkets
발행일 2017년 01월 상품 코드 326050
페이지 정보 영문 156 Pages
가격
US $ 5,650 ₩ 6,377,700 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,650 ₩ 7,506,500 PDF by E-mail (5-user license) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,150 ₩ 9,199,700 PDF by E-mail (Corporate License) help
기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없지만, 동일 국가의 동일 사업장에 한정되며 해외지점 등은 포함되지 않습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,000 ₩ 11,288,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세계의 혈액 스크리닝 시장 예측(-2021년) : 기술별(핵산증폭(rPCR), ELISA(CLIA, 형광측정), 신속검사, NGS, 웨스턴블로팅), 제품별(설비, 시약 및 키트, 소프트웨어), 최종사용자별(혈액은행, 병원) Blood Screening Market by Technology (Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecasts to 2021
발행일: 2017년 01월 페이지 정보 : 영문 156 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

세계의 혈액 스크리닝 시장은 2016년 17억 6,000만 달러에서 연평균 성장률(CAGR) 9.7%로 확대되어 2021년까지 28억 달러에 이를 것으로 예측됩니다. 그 중에서도 핵산검사(NAT) 부문이 가장 높은 성장률로 성장할 전망입니다.

세계의 혈액 스크리닝(Blood Screening) 시장에 대해 조사했으며, 시장 동향, 기술별, 제품별, 최종사용자별, 지역별 동향, 주요 시장 진출 기업 개요 등의 정보를 전해드립니다.

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 주요 조사 결과

제5장 시장 개요

  • 서론
  • 시장 동향
    • 성장 촉진요인
    • 성장 저해요인
    • 기회
    • 해결해야 할 과제

제6장 기술별 시장

  • 서론
  • 수량별 시장
  • 핵산검사
  • 효소결합면역흡착검사(ELISA)
  • 신속검사
  • 웨스턴블롯검사
  • 차세대 시퀀싱(NGS)

제7장 제품 및 서비스별 시장

  • 서론
  • 시약 및 키트
  • 설비
  • 소프트웨어 및 서비스

제8장 최종사용자별 시장

  • 서론
  • 혈액은행
  • 병원

제9장 지역별 시장

  • 서론
  • 북미
  • 유럽
  • 아시아
  • 기타

제10장 경쟁 구도

  • 개요
  • 시장 점유율 분석
  • 경쟁 상황과 동향
    • 제품 출시
    • 규제 인가
    • 협정
    • 제휴
    • 인수
    • 확충

제11장 기업 개요

  • 서론
  • GRIFOLS
  • F. HOFFMANN-LA ROCHE
  • ABBOTT LABORATORIES
  • BIOMERIEUX
  • BIO-RAD LABORATORIES, INC.
  • SIEMENS HEALTHINEERS
  • ORTHO CLINICAL DIAGNOSTICS, INC.
  • THERMO FISHER SCIENTIFIC, INC.
  • BECKMAN COULTER
  • BECTON, DICKINSON AND COMPANY

제12장 부록

KSM 17.01.18

영문목차

The blood screening market is expected to reach USD 2.80 billion by 2021 from USD 1.76 billion in 2016, at a CAGR of 9.7%. The global blood screening market is categorized based on technology, product & service, end user, and region. The technology segment includes nucleic acid tests (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS). The NAT segment is expected to grow at the highest CAGR during the forecast period. Major factors contributing to the growth in this segment are increasing number of blood donations, rising incidence of various infectious diseases, and increasing disposable income to pay for advanced blood screening procedures including NAT-test.

On the basis of product & service, the market is segmented into reagents & kits, instruments, and software & services. In 2016, the reagents and kits segment is expected to account for the largest share of the market. The repeated usage of reagents and kits is the key driving factor driving the growth of this segment.

On the basis of end user, the market is segmented into blood banks and hospitals. In 2016, the blood banks segment is expected to account for the largest of the market. This is primarily due to the increasing number of organ transplantation surgeries, increasing demand for donated blood, rising awareness regarding the safety of blood, and increasing number of donations worldwide.

Geographically, the blood screening market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The growth of this market can be attributed to the increasing adoption of nucleic acid tests (NAT) in this region. In addition, the increasing participation of various government associations in blood donations and screening & transfusion activities also supports the growth of the North American blood screening market.

Globally, the blood screening market is witnessing substantial growth due to factors such as increasing number of blood donations and blood donors, growing affordability and adoption of nucleic acid test (NAT) for blood screening, rising awareness regarding the safety of donated blood, growing demand for donated blood, and increasing prevalence/incidence of infectious diseases.

The major players in this market include: Grifols (Spain), Siemens Healthineers (Germany), Roche Diagnostics (Switzerland), Ortho Clinical Diagnostics, Inc. (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), bioMerieux (France), Beckman Coulter, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Becton, Dickinson and Company (U.S.).

Research Coverage:

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The abovementioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the blood screening market.

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the blood screening market. The report analyses the blood screening market by technology, product & service, end user, and region
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the blood screening market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the blood screening market
  • Market Development: Comprehensive information about emerging markets. This report analyses the market for various blood screening products across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the blood screening market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. SECONDARY DATA
    • 2.1.1. KEY DATA FROM SECONDARY SOURCES
  • 2.2. PRIMARY DATA
    • 2.2.1. KEY DATA FROM PRIMARY SOURCES
  • 2.3. MARKET SIZE ESTIMATION
    • 2.3.1. BOTTOM-UP APPROACH
    • 2.3.2. TOP-DOWN APPROACH
  • 2.4. MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. BLOOD SCREENING MARKET
  • 4.2. BLOOD SCREENING MARKET, BY REGION & TECHNOLOGY

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing number of blood donations and blood donors
      • 5.2.1.2. Increasing demand of donated blood
      • 5.2.1.3. Rising prevalence of infectious diseases
      • 5.2.1.4. Growing affordability and adoption of NAT for blood screening
      • 5.2.1.5. Rising awareness about the safety of donated blood
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Capital expenditure and operating costs of NAT
      • 5.2.2.2. Lack of regulations mandating the use of NAT in developing countries
      • 5.2.2.3. Emergence of alternative technologies
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Pathogen reduction technology
      • 5.2.3.2. Multiplex tests
      • 5.2.3.3. Emerging economies
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Price reduction

6. BLOOD SCREENING MARKET, BY TECHNOLOGY

  • 6.1. INTRODUCTION
  • 6.2. BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS CONDUCTED)
  • 6.3. NAT
    • 6.3.1. TMA
    • 6.3.2. REAL-TIME POLYMERASE CHAIN REACTION (PCR)
  • 6.4. ELISA
    • 6.4.1. ELISA MARKET, BY PLATFORM
      • 6.4.1.1. CLIA
      • 6.4.1.2. FIA
      • 6.4.1.3. CI
    • 6.4.2. ELISA MARKET, BY GENERATION
      • 6.4.2.1. First-generation ELISA
      • 6.4.2.2. Second-generation ELISA
      • 6.4.2.3. Third-generation ELISA
      • 6.4.2.4. Fourth-generation & above
  • 6.5. RAPID TESTS
  • 6.6. WESTERN BLOT ASSAY
  • 6.7. NGS

7. BLOOD SCREENING MARKET, BY PRODUCT AND SERVICE

  • 7.1. INTRODUCTION
  • 7.2. REAGENTS & KITS
    • 7.2.1. NAT REAGENTS & KITS
      • 7.2.1.1. Enzymes and polymerases
      • 7.2.1.2. Standards and controls
      • 7.2.1.3. Probes and primers
      • 7.2.1.4. Buffers, nucleotides, and solutions
      • 7.2.1.5. Labeling and detection reagents
    • 7.2.2. ELISA REAGENTS & KITS
      • 7.2.2.1. Immunosorbents
      • 7.2.2.2. Controls
      • 7.2.2.3. Conjugates (Antigen or antibody-conjugated enzyme)
      • 7.2.2.4. Substrates (of enzymes)
      • 7.2.2.5. Sample diluents and wash solutions
    • 7.2.3. OTHER REAGENTS
  • 7.3. INSTRUMENTS
    • 7.3.1. RENTAL PURCHASE
    • 7.3.2. OUTRIGHT PURCHASE
  • 7.4. SOFTWARE & SERVICES

8. BLOOD SCREENING MARKET, BY END USER

  • 8.1. INTRODUCTION
  • 8.2. BLOOD BANKS
  • 8.3. HOSPITALS

9. BLOOD SCREENING MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. U.S.
    • 9.2.2. CANADA
  • 9.3. EUROPE
    • 9.3.1. GERMANY
    • 9.3.2. FRANCE
    • 9.3.3. U.K.
    • 9.3.4. ITALY
    • 9.3.5. SPAIN
    • 9.3.6. ROE
  • 9.4. ASIA
    • 9.4.1. JAPAN
    • 9.4.2. CHINA
    • 9.4.3. INDIA
    • 9.4.4. ROA
  • 9.5. ROW

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS
    • 10.2.1. MARKET SHARE ANALYSIS FOR NAT
    • 10.2.2. BLOOD SCREENING MARKET SHARE ANALYSIS
  • 10.3. COMPETITIVE SITUATIONS AND TRENDS
    • 10.3.1. PRODUCT LAUNCHES
    • 10.3.2. REGULATORY APPROVALS
    • 10.3.3. AGREEMENTS
    • 10.3.4. PARTNERSHIPS
    • 10.3.5. ACQUISITIONS
    • 10.3.6. EXPANSIONS

11. COMPANY PROFILES (Business Overview, Products Offered, Recent Developments, MnM View)*

  • 11.1. INTRODUCTION
  • 11.2. GRIFOLS
  • 11.3. F. HOFFMANN-LA ROCHE
  • 11.4. ABBOTT LABORATORIES
  • 11.5. BIOMERIEUX
  • 11.6. BIO-RAD LABORATORIES, INC.
  • 11.7. SIEMENS HEALTHINEERS (A SUBSIDIARY OF SIEMENS AG)
  • 11.8. ORTHO CLINICAL DIAGNOSTICS, INC.
  • 11.9. THERMO FISHER SCIENTIFIC, INC.
  • 11.10. BECKMAN COULTER (A SUBSIDIARY OF DANAHER CORPORATION)
  • 11.11. BD

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. DISCUSSION GUIDE
  • 12.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.4. AVAILABLE CUSTOMIZATIONS
  • 12.5. RELATED REPORTS
  • 12.6. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 2: GLOBAL BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS), 2015
  • TABLE 3: NORTH AMERICA: BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS), 2015
  • TABLE 4: EUROPE: BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS), 2015
  • TABLE 5: ASIA: BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS), 2015
  • TABLE 6: BLOOD SCREENING MARKET SIZE FOR NAT, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 7: BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 8: TMA MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 9: REAL-TIME PCR MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 10: BLOOD SCREENING MARKET SIZE FOR ELISA, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 11: BLOOD SCREENING MARKET SIZE FOR ELISA, BY PLATFORM, 2014-2021 (USD MILLION)
  • TABLE 12: CLIA MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 13: FIA MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 14: CI MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 15: BLOOD SCREENING MARKET SIZE FOR ELISA, BY GENERATION, 2014-2021 (USD MILLION)
  • TABLE 16: FIRST-GENERATION ELISA MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 17: SECOND-GENERATION ELISA MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 18: THIRD-GENERATION ELISA MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 19: FOURTH-GENERATION ELISA MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 20: BLOOD SCREENING MARKET SIZE FOR RAPID TESTS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 21: BLOOD SCREENING MARKET SIZE FOR WESTERN BLOT ASSAY, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 22: BLOOD SCREENING MARKET SIZE FOR NGS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 23: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 24: BLOOD SCREENING REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 25: BLOOD SCREENING REAGENTS & KITS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 26: NAT REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 27: NAT REAGENTS & KITS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 28: ELISA REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 29: ELISA REAGENTS & KITS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 30: OTHER REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 31: BLOOD SCREENING INSTRUMENTS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 32: BLOOD SCREENING INSTRUMENTS MARKET SIZE, BY PURCHASE MODE, 2014-2021 (USD MILLION)
  • TABLE 33: RENTAL PURCHASE MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 34: OUTRIGHT PURCHASE MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 35: BLOOD SCREENING SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 36: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 37: BLOOD SCREENING MARKET SIZE FOR BLOOD BANKS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 38: BLOOD SCREENING MARKET SIZE FOR HOSPITALS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 39: GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2012-2019 (USD MILLION)
  • TABLE 40: NORTH AMERICA: BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 41: NORTH AMERICA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 42: NORTH AMERICA: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 43: NORTH AMERICA: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 44: NUMBER OF ORGAN TRANSPLANTATIONS PERFORMED IN THE U.S., 2014-2015
  • TABLE 45: U.S.: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 46: U.S.: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 47: U.S.: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 48: CANADA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 49: CANADA: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 50: CANADA: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 51: EUROPE: BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 52: EUROPE: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 53: EUROPE: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 54: EUROPE: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 55: GERMANY: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 56: GERMANY: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 57: GERMANY: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 58: FRANCE: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 59: FRANCE: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 60: FRANCE: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 61: U.K.: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 62: U.K.: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 63: U.K.: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 64: ITALY: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 65: ITALY: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 66: ITALY: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 67: SPAIN: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 68: SPAIN: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 69: SPAIN: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 70: ROE: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 71: ROE: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 72: ROE: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 73: ASIA: BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 74: ASIA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 75: ASIA: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 76: ASIA: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 77: JAPAN: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 78: JAPAN: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 79: JAPAN: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 80: CHINA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 81: CHINA: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 82: CHINA: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 83: INDIA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 84: INDIA: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 85: INDIA: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 86: ROA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 87: ROA: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 88: ROA: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 89: ROW: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 90: ROW: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014-2021 (USD MILLION)
  • TABLE 91: ROW: BLOOD SCREENING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 92: PRODUCT LAUNCHES, 2013-2016
  • TABLE 93: REGULATORY APPROVALS, 2013-2016
  • TABLE 94: AGREEMENTS, 2013-2016
  • TABLE 95: PARTNERSHIPS, 2013-2016
  • TABLE 96: ACQUISITIONS, 2013-2016
  • TABLE 97: EXPANSIONS, 2013-2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BLOOD SCREENING MARKET: BOTTOM-UP APPROACH
  • FIGURE 3: TOP-DOWN APPROACH
  • FIGURE 4: DATA TRIANGULATION METHODOLOGY
  • FIGURE 5: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2016 VS. 2021 (USD BILLION)
  • FIGURE 6: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2016 VS. 2021 (USD BILLION)
  • FIGURE 7: BLOOD SCREENING MARKET SIZE, BY END USER, 2016 VS. 2021 (USD BILLION)
  • FIGURE 8: NORTH AMERICA ACCOUNTED FOR THE HIGHEST SHARE OF THE BLOOD SCREENING MARKET IN 2016
  • FIGURE 9: BLOOD SCREENING MARKET IS EXPECTED TO OFFER LUCRATIVE GROWTH OPPORTUNITIES IN THE FORECAST PERIOD
  • FIGURE 10: NAT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 11: ASIA IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 12: GLOBAL INCIDENCE OF CANCER
  • FIGURE 13: NAT TESTING WILL CONTINUE TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 14: REAGENTS & KITS SEGMENT IS EXPECTED TO HOLD THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD
  • FIGURE 15: BLOOD BANKS SEGMENT WILL CONTINUE TO DOMINATE THE BLOOD SCREENING MARKET DURING THE FORECAST PERIOD
  • FIGURE 16: EMERGING MARKETS OFFER SIGNIFICANT GROWTH OPPORTUNITIES
  • FIGURE 17: ASIAN BLOOD SCREENING MARKET IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 18: NORTH AMERICA: MARKET SNAPSHOT
  • FIGURE 19: REAGENTS & KITS SEGMENT TO HOLD LARGEST SHARE IN THE U.S. MARKET
  • FIGURE 20: EUROPE: MARKET SNAPSHOT
  • FIGURE 21: GERMANY: BLOOD SCREENING MARKET, BY PRODUCT AND SERVICE
  • FIGURE 22: ASIA: BLOOD SCREENING MARKET SNAPSHOT
  • FIGURE 23: ELISA SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE JAPANESE MARKET DURING 2016-2021
  • FIGURE 24: BLOOD BANKS END-USER SEGMENT IS EXPECTED TO CONTINUE TO DOMINATE THE INDIAN BLOOD SCREENING MARKET UNTIL 2021
  • FIGURE 25: ROW: MARKET SNAPSHOT
  • FIGURE 26: PRODUCT LAUNCHES WAS THE KEY STRATEGY ADOPTED BY LEADING PLAYERS
  • FIGURE 27: NAT BLOOD SCREENING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 28: BLOOD SCREENING MARKET SHARE ANALYSIS, BY KEY COMPANY, 2015
  • FIGURE 29: BATTLE FOR MARKET SHARE: PRODUCT LAUNCHES, PARTNERSHIPS AND AGREEMENTS, THE KEY GROWTH STRATEGIES ADOPTED BETWEEN 2014 AND 2016
  • FIGURE 30: PRODUCT BENCHMARKING OF THE TOP FIVE PLAYERS
  • FIGURE 31: GRIFOLS: COMPANY SNAPSHOT
  • FIGURE 32: F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
  • FIGURE 33: ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 34: BIOMERIEUX: COMPANY SNAPSHOT
  • FIGURE 35: BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • FIGURE 36: SIEMENS AG: COMPANY SNAPSHOT
  • FIGURE 37: THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • FIGURE 38: DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 39: BD: COMPANY SNAPSHOT
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research